Levi & Korsinsky notifies investors that it has commenced an investigation into Byrna Technologies Inc. (NASDAQ: BYRN) concerning potential violations of the federal securities laws.
On October 29, 2024, Bonitas Research issued a report questioning Byrna’s primary sales channels, sales growth, and profitability. The report states that “Byrna’s earnings call highlighted the specific importance of its ‘Premier Dealer’ network and disclosed Byrna had twenty (20) ‘Premier Dealers’ as of April 5, 2024. We found some Byrna ‘Premier Dealers’ were secondary businesses using ad-hoc shooting ranges in garages and back alleys with little to no retail presence.” Bonitas Research also contacted 20% of Byrna’s Authorized Dealers, revealing multiple ‘Authorized Dealers’ with no online presence nor independent retail storefronts, including a car wash, a tea shop, a uniform embroidery shop, and a barbershop. We found that Byrna’s “Authorized Dealer” list included storefronts that did not carry launchers in stock and had not placed a restocking order in the last 90 days.”
If you suffered a loss on your Byrna Technologies Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) concerning potential violations of the federal securities laws.
On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines. Specifically, the Company reported earnings per share (“EPS”) of $0.12, missing EPS expectations of $0.29 by nearly 60%. TransMedics also reported revenue of $108.8 million, falling short of analysts’ $115 million estimate. Following this news, TransMedics stock dropped over 24% in after-hours trading.
If you suffered a loss on your TransMedics Group, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into DZS Inc. (OTC: DZSI) concerning potential violations of the federal securities laws.
The investigation concerns whether DZS and certain of its directors and/or officers failed to disclose to shareholders that: (i) certain of the Company's financial statements contained errors that would require DZS to restate its previously filed financial statements; and (ii) DZS had ongoing undisclosed issues with its internal controls over financial reporting.
If you suffered a loss on your DZS Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into DoubleVerify Holdings, Inc. (NYSE: DV) concerning potential violations of the federal securities laws.
DoubleVerify reported its quarterly financial results on May 7, 2024, including a reduction in its full-year revenue guidance. Following this news, shares of DoubleVerify fell over 38% on the next day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your DoubleVerify Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into eXp World Holdings, Inc. (NASDAQ: EXPI) concerning potential violations of the federal securities laws.
The investigation concerns whether eXp and certain of its directors and/or officers failed to disclose to shareholders that: (i) the Company's top agents, also known as "Influencers," and executives were accused of sexually assaulting eXp's real estate agents at Company events; (ii) the Company lacked a process and system to detect and report sexual misconduct to the Company's Board of Directors (the "Board"); and (iii) the Board failed to effectively respond to reports it received of sexual misconduct.
If you suffered a loss on your eXp World Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Unisys Corporation (NYSE: UIS) concerning potential violations of the federal securities laws.
The Securities and Exchange Commission ("SEC") announced on October 22, 2024, that it had charged four companies, including Unisys, with "making materially misleading disclosures regarding cybersecurity risks and intrusions." Further, the SEC also charged Unisys with disclosure controls and procedures violations. Following this news, Unisys' stock fell over 8% on the same day.
If you suffered a loss on your Unisys Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Treace Medical Concepts, Inc. (NASDAQ: TMCI) concerning potential violations of the federal securities laws.
On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on “competitive pressure in its business.” Following this news, Treace’s stock price fell by $6.95 per share, or approximately 62% on the same day.
If you suffered a loss on your Treace Medical Concepts, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Mercer International Inc. (NASDAQ: MERC) concerning potential violations of the federal securities laws.
On October 16, 2024, Mercer issued a press release announcing its preliminary financial results for the third quarter of 2024. In the press release, Mercer stated that "our operating results for the quarter were constrained due to the occurrence of several unrelated events that impacted pulp production, including the previously announced unscheduled downtime of 23 days (approximately 35,500 ADMTs [air-dried metric tons]) at our Mercer Peace River mill, a slower than normal maintenance start-up and other production upsets at our Stendal Mill (approximately 26,500 ADMTs) and isolated mechanical incidents at our Celgar mill (approximately 9,200 ADMTs)." Following this news, Mercer's stock price fell over 3% on October 17, 2024.
If you suffered a loss on your Mercer International Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into CSX Corporation (NASDAQ: CSX) concerning potential violations of the federal securities laws.
CSX is the subject of a Bloomberg article published on October 17, 2024, which states that the Company "received a subpoena from the US Securities and Exchange Commission focused on previously disclosed accounting errors and certain non-financial performance metrics." According to the article, "The subpoena asked the railroad company to produce documents about accounting mistakes CSX disclosed in its previous quarterly report, according to a regulatory filing on Thursday. The company received the subpoena this month and is cooperating with the probe, CSX said in the filing." The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your CSX Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Stride, Inc. (NYSE: LRN) concerning potential violations of the federal securities laws.
On October 16, 2024, after a report from Fuzzy Panda Research alleged that Stride has been inflating its earnings by misleading investors about the impact of federal COVID-19 relief funds. The report claims that more than 25% of Stride’s EBITDA came from Elementary and Secondary School Emergency Relief (ESSER) funds, which expired in September 2024. The report also accuses Stride of hiding “ghost students” and failing to disclose schools leaving the company, alongside allegations of overbilling and fraudulent reimbursement claims. Following this news, shares of Stride fell 5% the same day.
If you suffered a loss on your Stride, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Service Properties Trust (NASDAQ: SVC) concerning potential violations of the federal securities laws.
On October 16, 2024, SVC announced a quarterly dividend of $0.01 per share, representing a 95% decrease from its prior dividend of $0.20 per share. SVC also announced plans to sell roughly half of its hotel properties in order to boost its liquidity and pay down debt. Following this news, SVC's stock price fell over 16% the same day.
If you suffered a loss on your Service Properties Trust securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Shoals Technologies Group, Inc. (NASDAQ: SHLS) concerning potential violations of the federal securities laws.
The investigation concerns whether Shoals and certain of its directors and/or officers failed to disclose to shareholders that: (i) certain of the Company's products used for solar power generation were not of the highest levels of quality and reliability as Shoals claimed; (ii) the Company received numerous reports of defects in wire harnesses it had installed in a number of solar fields; and (iii) it would cost Shoals millions of dollars to remediate the defects with its products.
If you suffered a loss on your Shoals Technologies Group, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) concerning potential violations of the federal securities laws.
On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. Biodexa disclosed that of the four patients who were enrolled in Cohort A of the study, two are now deceased, with one achieving an overall survival of 12 months and the other 13 months since the start of treatment. Follow this news, Biodexa's stock price fell over 7% on the same day.
If you suffered a loss on your Biodexa Pharmaceuticals Plc securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Rayonier Advanced Materials Inc. (NYSE: RYAM) concerning potential violations of the federal securities laws.
On October 14, 2024, Rayonier issued a press release "report[ing] that an isolated fire occurred at its Jesup, Georgia facility on October 11 at approximately 6 p.m. during planned maintenance activity[,]" advising that "[w]hile the plant's C line operations have resumed, the A and B lines will remain offline for repairs with a target start date the week of October 28. Rayonier stated that "[w]hile the Company continues to assess the financial cost of the incident, the EBITDA impact is currently expected to be in the range of $15 to $20 million, subject to any potential insurance recovery." Following this news, Rayonier's stock price fell over 9% on the same day.
If you suffered a loss on your Rayonier Advanced Materials Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Novavax, Inc. (NASDAQ: NVAX) concerning potential violations of the federal securities laws.
On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company’s combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine. The hold was placed following a “serious adverse event of motor neuropathy” that occurred in a CIC Phase 2 trial participant outside the U.S., who received the vaccine in January of 2023. Following this news, NVAX’s stock price fell by $2.18 per share, or approximately 17% in premarket trading.
If you suffered a loss on your Novavax, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Tesla, Inc. (NASDAQ: TSLA) concerning potential violations of the federal securities laws.
On October 10, 2024, Tesla unveiled the Company's Cybercab self-driving concept car at the Company's "We, Robot" event and announced plans to create a fleet of autonomous vehicles and robots, with the goal of starting production before 2027. Analysts and investors did not react positively to Tesla's announcements. An analyst at Jefferies published a note entitled "We, Underwhelmed", analysts at Barclays said that the revelations failed to highlight any near-term opportunities for Tesla, and Piper Sandler analysts opined that "most trading-oriented firms will be underwhelmed by the robo-taxi unveiling." Following this news, the Company's stock price fell over 8% on October 11, 2024.
If you suffered a loss on your Tesla, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Shattuck Labs, Inc. (NASDAQ: STTK) concerning potential violations of the federal securities laws.
On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data. Specifically, Shattuck's decision came after an interim Phase 1 readout indicated that SL-172154, compared to azacitidine monotherapy, failed to improve median overall survival in certain patients with myeloid leukemia and myelodysplastic syndromes in combination with azacitidine. Following this news, Shattuck's stock price fell over 44% on the same day.
If you suffered a loss on your Shattuck Labs, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Xometry, Inc. (NASDAQ: XMTR) concerning potential violations of the federal securities laws.
On March 1, 2023, Xometry announced an adjusted EBITDA loss of $14.2 million for the fourth quarter of 2022 due to a “revenue shortfall” and “lower gross margins quarter-over-quarter.” The Company blamed “macroeconomic factors” including inflation that “changed” supplier behavior and “slowing demand.” Further, the Company announced that it would be implementing a “5-point strategic plan” that included “aggressively” reducing operating expenses. Xometry also announced its full year financial guidance for fiscal year 2023 which was significantly worse than analysts had been expecting, including an adjusted EBITDA loss of between $20 million and $22 million instead of the $7.3 million loss projected by analysts. Following this news, Xometry’s stock price fell by $12.01 per share, or approximately 40%, to close at $18.40 per share.
If you suffered a loss on your Xometry, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into First Solar, Inc. (NASDAQ: FSLR) concerning potential violations of the federal securities laws.
On October 10, 2024, Jefferies analysts pared their expectations for FirstSolar's upcoming third-quarter results, stating that "[g]oing into 3Q, we expect a slight miss with lower volume versus consensus" and that "[w]e also lower volume estimates for 2025/2026, which are 8%/4% below consensus and are below 2024 guidance." Jefferies said that it expected First Solar's focus this earnings season to be on potential delays, impact on module pricing from Antidumping and Countervailing Duties determinations, and thoughts on selling excess Indian capacity into the U.S. Following this news, First Solar's stock price fell over 9% on October 10, 2024.
If you suffered a loss on your First Solar, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning potential violations of the federal securities laws.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP. The news caused a precipitous decline in the price of ADMA Biologics stock. ADMA Biologics stock price fell over 20% on October 10, 2024.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into CAE Inc. (NYSE: CAE) concerning potential violations of the federal securities laws.
Investors who purchased CAE on the New York Stock Exchange (“NYSE”) may have been affected by violations of federal securities laws. Specifically, CAE executives allegedly made false statements and/or concealed that: (i) several of CAE’s pre-COVID fixed-price defense contracts had incurred severe cost overruns due to supply chain and labor issues – as the segment was significantly impacted by the pandemic – which dented the segment’s profit and operating margin; and (ii) CAE failed to successfully reduce hard costs and achieve a sufficient level of operational efficiency, particularly with respect to such contracts, necessitating a re-baselining of the defense business and significant associated charges.
If you suffered a loss on your CAE Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Torrid Holdings Inc. (NYSE: CURV) concerning potential violations of the federal securities laws.
On October 7, 2024, Torrid announced the termination of "Ms. Elizabeth Muñoz-Guzman, the [Company's] Executive Vice President and Chief Creative Officer . . . effective as of October 4, 2024[.]" Following this news, Torrid's stock price fell over 10% the same day.
If you suffered a loss on your Torrid Holdings Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Beyond, Inc. (NYSE: BYON) concerning potential violations of the federal securities laws.
After the market closed on May 6, 2024, Beyond announced the company's first quarter 2024 financial results and revealed first quarter total net revenue of $382 million, an increase of only 0.3% year-over-year, and a first quarter net loss of $74 million. Additionally, Beyond declined to reiterate its previously-issued goal to achieve $2 billion of revenue in 2024 and a $3 billion revenue run rate by the end of 2025. Following this news, Beyond's share price fell over 24% on May 7, 2024.
If you suffered a loss on your Beyond, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Franklin Resources, Inc. (NYSE: BEN) concerning potential violations of the federal securities laws.
Franklin subsidiary Western Asset Management Company issued a press release on August 21, 2024, announcing that co-Chief Investment Officer Ken Leech “is on a leave of absence, effective immediately” after “receiv[ing] a Wells Notice from the Staff of the U.S. Securities and Exchange Commission”. That same day, Bloomberg reported that “[f]ederal prosecutors in New York are investigating whether a Western Asset Management executive allocated winning trades to favored accounts, as part of a criminal probe into a practice known as ‘cherry-picking.’” Following this news, Franklin’s stock price fell over 12% on August 21, 2024.
If you suffered a loss on your Franklin Resources, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Nomura Holdings, Inc. (NYSE: NMR) concerning potential violations of the federal securities laws.
Media outlets reported on September 30, 2024, that Nomura was excluded as lead manager for several yen bond deals after an investigation by Japan's securities watchdog into suspected market manipulation in government bond futures found rule violations by Nomura. Following this news, Nomura's American depositary receipt ("ADR") price fell over 4% on September 30, 2024.
If you suffered a loss on your Nomura Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential violations of the federal securities laws.
Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. Following this news, Medpace's stock price fell over 9% on September 25, 2024.
If you suffered a loss on your Medpace Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Humana Inc. (NYSE: HUM) concerning potential violations of the federal securities laws.
On May 1, 2025, the U.S. Department of Justice announced it had filed a False Claims Act complaint against several health insurance companies and insurance broker organizations, including Humana. The complaint alleged "that from 2016 through at least 2021, the defendant insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments into the insurers' Medicare Advantage plans." On this news, Humana's stock price fell $6.20 per share, or 2.36%.
If you suffered a loss on your Humana Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Travere Therapeutics, Inc. (NASDAQ: TVTX) concerning potential violations of the federal securities laws.
Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU)." Travere stated that "[t]he voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study" and that "[t]he voluntary enrollment pause was enacted following the Company's determination that the desired drug substance profile was not achieved in the recent scale-up process." Following this news, Travere's stock price fell over 6% on September 27, 2024.
If you suffered a loss on your Travere Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Dollar General Corporation (NYSE: DG) concerning potential violations of the federal securities laws.
Dollar General lowered its outlook for same-store sales and earnings per share on August 29, 2024. According to CNBC, CEO Todd Vasos said, ""While we believe the softer sales trends are partially attributable to a core customer who feels financially constrained, we know the importance of controlling what we can control." Following this news, shares of Dollar General dropped 32% on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Dollar General Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Laser Photonics Corporation (NASDAQ: LASE) concerning potential violations of the federal securities laws.
Laser Photonics disclosed in a filing with the U.S. Securities and Exchange Commission on May 29, 2025, that it had “received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (‘Nasdaq’) stating that since it had not received the Company’s Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the ‘Initial Delinquent Filing’), the Company does not comply with Nasdaq’s Listing Rules for continued listing.” Laser Photonics said that “the Company has until June 16, 2025, to submit a plan to regain compliance with respect to these delinquent reports.” Laser Photonics specified that the delay was “primarily due to [Laser Photonics’] acquisition of certain assets of CMS in November 2024 . . . , approximately six weeks before the end of [Laser Photonics’] fiscal year, for approximately $1 million out of the bankruptcy proceedings of CMS’s former parent company.” Following this news, Laser Photonics’ stock price fell over 6% on May 30, 2025.
If you suffered a loss on your Laser Photonics Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into SAP SE (NYSE: SAP) concerning potential violations of the federal securities laws.
On September 25, 2024, Bloomberg News reported that the U.S. Department of Justice was investigating SAP and other companies for potentially conspiring to overcharge U.S. government agencies over the course of a decade, by "fix[ing] prices on sales to the U.S. military and other parts of the government". Following this news, SAP's American depositary receipt ("ADR") price fell over 3% on September 25, 2024.
If you suffered a loss on your SAP SE securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into SIGA Technologies, Inc. (NASDAQ: SIGA) concerning potential violations of the federal securities laws.
On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial. According to Dr. Varma, the media "spin" campaign was designed to convince investors "not to dump the stock, thinking that the Company was worthless" while conceding that pursuit of TPOXX as a treatment for mpox might not even be worth it because "there's only a few thousand cases in the United States." Following this news, the stock dropped over 15% on September 25, 2024.
If you suffered a loss on your SIGA Technologies, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Stitch Fix, Inc. (NADSAQ: SFIX) concerning potential violations of the federal securities laws.
Stitch Fix issued a press release on September 24, 2024, "announc[ing] its financial results for the fourth quarter and full fiscal year 2024, ended August 3, 2024." Among other items, Stitch Fix disclosed that with fewer active clients in both the fourth quarter and full year, the Company experienced a 12.4% drop in sales in the quarter, resulting in a wider-than-expected loss. Anticipating declining sales in the first quarter and full year 2025, Stich Fix provided guidance for both the quarter and year that fell short of analyst expectations. Following this news, Stitch Fix's stock price fell over 39% on September 25, 2024.
If you suffered a loss on your Stitch Fix, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Light & Wonder, Inc. (NASDAQ: LNW) concerning potential violations of the federal securities laws.
Aristocrat Technologies ("Aristocrat") sued L&W in the U.S. District Court for the District of Nevada in February 2024, alleging that L&W's "Dragon Train" series of slot machines bears similarities to Aristocrat's own "Dragon Link" series and questioning the role of two former Aristocrat designers in developing "Dragon Train". On September 23, 2024, the court entered an order enjoining L&W from "any continued or planned sale, leasing, or other commercialization of Dragon Train", finding a high likelihood that Aristocrat would prevail on the merits of its lawsuit. Following this news, L&W's stock price fell over 19% on September 24, 2024.
If you suffered a loss on your Light & Wonder, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into 2seventy bio, Inc. (NASDAQ: TSVT) concerning potential violations of the federal securities laws.
2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant." Explaining the decision, the Company's Chief Executive Officer cited "a greatly improved NDMM treatment landscape and . . . our rigorous review of the business case for the KarMMa-9 study". Following this news, 2seventy bio's stock price fell over 9% on September 25, 2024.
If you suffered a loss on your 2seventy bio, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into VinFast Auto Ltd. (NASDAQ: VFS) concerning potential violations of the federal securities laws.
VinFast issued a press release on September 20, 2024, reporting the Company's financial results for the second quarter of 2024. Among other items, VinFast reported a gross loss of $224 million for the quarter, which the Company attributed primarily to an impairment charge on Net Residual Value of $104 million. Following this news, VinFast's stock price fell over 7% on September 20, 2024.
If you suffered a loss on your VinFast Auto Ltd. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) concerning potential violations of the federal securities laws.
On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony’s narcolepsy drug, Wakix (pitolisant). The report raised numerous concerns related to patient health, drug efficacy, and trial reliability, as well as allegations the Company engaged in price-gouging, false advertising, and a significant off-label and physician kickback scheme. Following this news, Harmony’s stock price fell by $10.70 per share to close at $30.80 per share.
If you suffered a loss on your Harmony Biosciences Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) concerning potential violations of the federal securities laws.
Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL)." Following this news, Vanda's stock price fell sharply during intraday trading on September 19, 2024.
If you suffered a loss on your Vanda Pharmaceuticals Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Progyny, Inc. (NASDAQ: PGNY) concerning potential violations of the federal securities laws.
Progyny disclosed in a filing with the U.S. Securities and Exchange Commission on September 18, 2024, that the Company "was recently notified by a significant client (the ‘Client') that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025." On September 19, 2024, JMP Securities downgraded Progyny to Market Perform from Outperform, stating that "the loss of [Progyny's] largest client causes us to appropriately contemplate the potential for lower retention rates going forward." Following this news, Progyny's stock price fell sharply during intraday trading on September 19, 2024.
If you suffered a loss on your Progyny, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Swvl Holdings Corp. (NASDAQ: SWVL) concerning potential violations of the federal securities laws.
Wolfpack Research ("Wolfpack") published a report on September 17, 2024, entitled "SWVL, a ‘Transportation-as-a-Service' Start-up Appears to Be a Few Breaths Away from Bankruptcy". Citing "research into the company, including on-the-ground due diligence in Egypt", the Wolfpack report alleged, among other things, "that SWVL's operations are grinding to a halt as they run out of money" and that very few rides appeared to be available on the Company's bus-sharing app in Cairo, Swvl's primary market. Following this news, Swvl's stock price fell over 43% on September 17, 2024.
If you suffered a loss on your Swvl Holdings Corp. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Gogoro Inc. (NASDAQ: GGR) concerning potential violations of the federal securities laws.
Gogoro announced the resignation of its Chief Executive Officer Horace Luke on September 13, 2024. Mr. Luke's resignation followed "internal investigations into allegations in recent media reports that the Company incorporated imported components into certain of its vehicles in violation of the requirement of the Taiwan government that certain core components of the electric scooters shall be produced domestically in order to be qualified for the subsidies to purchasers." Gogoro stated that "during such investigations, the Company has identified certain irregularities in supply chain which caused the Company to inadvertently incorporate certain imported components in some of its vehicles." Following this news, Gogoro's stock price fell over 14% on September 16, 2024.
If you suffered a loss on your Gogoro Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Brookfield Business Partners L.P. (NYSE: BBU) concerning potential violations of the federal securities laws.
Brookfield purchased CDK Global ("CDK"), a provider of software to car dealerships, for $6.41 billion in April 2022. The Company's CDK unit announced on June 19, 2024, that it was investigating a cyberattack that resulted in it proactively shutting down all of its systems. This action caused massive disruption for car dealerships across North America. CDK later admitted the cyberattack and also that it was hacked a second time as it tried to restore its services. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Brookfield Business Partners L.P. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Adobe Inc. (NASDAQ: ADBE) concerning potential violations of the federal securities laws.
Adobe issued a press release on September 12, 2024, reporting financial results for the third quarter of its fiscal year 2024. Although Adobe reported net new annual recurring revenue of $44 million, exceeding guidance, its fourth quarter outlook fell short of consensus estimates by approximately $21 million. Following this news, Adobe's stock price fell over 8% on September 13, 2024.
If you suffered a loss on your Adobe Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Aviat Networks, Inc. (NASDAQ: AVNW) concerning potential violations of the federal securities laws.
Aviat announced on September 11, 2024, its inability to file the Annual Report on Form 10-K for the fiscal year ending June 28, 2024, within the prescribed deadline. The management of Aviat has reported the discovery of certain material weaknesses during its preliminary assessment of internal controls over financial reporting for the aforementioned fiscal year. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Aviat Networks, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Caleres, Inc. (NYSE: CAL) concerning potential violations of the federal securities laws.
Caleres issued a press release on May 29, 2025, reporting its financial results for the first quarter of 2025. Among other items, Caleres reported sales of only $614.2 million, representing a 6.8% year-over-year decline, which Caleres's Chief Financial Officer acknowledged "was below our expectations". The Company also suspended its guidance for 2025, citing "the uncertainty in the environment[.]" Following this news, Caleres's stock price fell over 18% on the same day.
If you suffered a loss on your Caleres, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Flux Power Holdings, Inc. (NASDAQ: FLUX) concerning potential violations of the federal securities laws.
On September 5, 2024, in a filing with the U.S. Securities and Exchange Commission ("SEC"), Flux disclosed that its Board of Directors had "concluded that the previously issued audited consolidated financial statements as of and for the fiscal year ended June 30, 2023 and the unaudited consolidated financial statements as of and for the quarters ended September 30, 2023, December 31, 2023, and March 31, 2024 (collectively, the ‘Prior Financial Statements'), which were filed with the [SEC] on September 21, 2023, November 9, 2023, February 8, 2024 and May 13, 2024, respectively, should no longer be relied upon because of errors in such financial statements relating to the improper accounting for inventory and a restatement should be undertaken. During the Company's preparation of financial statements for the year ended June 30, 2024, it became aware that (i) approximately $1.2 million of excess and obsolete inventory, primarily as a result of a change in battery cells from a new supplier, was not properly reserved or written-off in earlier periods resulting in an overstatement of inventory, and (ii) certain loaner service packs were improperly accounted for as finished goods inventory as of June 30, 2023 resulting in an overstatement of inventory of approximately $0.5 million. As a result, the Company concluded that the errors resulted in (i) an overstatement of inventory, current assets, total assets and accumulated deficit on its balance sheet, and (ii) an understatement of cost of sales and net loss, and overstatement of gross profit on its statement of operations in the Prior Financial Statements. The Company is also evaluating the impact that improper accounting for inventory had on other historical financial statements for previous quarterly and fiscal periods which also could include the audited consolidated financial statements as of and for the years ended June 30, 2022 and 2021, as well as the quarterly unaudited consolidated financial statements within the years ended June 30, 2022, 2021 and 2020." Following this news, Flux's stock price dropped over 5% on September 6, 2024.
If you suffered a loss on your Flux Power Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Under Armour, Inc. (NYSE: UA) concerning potential violations of the federal securities laws.
Under Armour issued a press release on September 9, 2024, "announc[ing] an update to its Fiscal 2025 restructuring plan, including additional initiatives to optimize the company's strategic supply chain capabilities and overall business performance." Among other items, Under Armour advised that "[f]ollowing further evaluation" of charges to be incurred "in connection with its Fiscal 2025 restructuring plan", Under Armour "now expect approximately $140 million to $160 million of pre-tax restructuring and related charges to be incurred in Fiscal 2025 and Fiscal 2026". Accordingly, Under Armour updated its fiscal 2025 outlook, projecting an operating loss in the range of $220 million to $240 million, compared to previous guidance of $194 million to $214 million. Following this news, Under Armour's stock price fell over 9% on September 10, 2024.
If you suffered a loss on your Under Armour, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Acadia Healthcare Company, Inc. (NASDAQ: ACHC) concerning potential violations of the federal securities laws.
The New York Times published a report on September 1, 2024, entitled "How a Leading Chain of Psychiatric Hospitals Traps Patients." The article stated, "Acadia Healthcare is one of America's largest chains of psychiatric hospitals. Since the pandemic exacerbated a national mental health crisis, the company's revenue has soared. [. . .] But a New York Times investigation found that some of that success was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary. In at least 12 of the 19 states where Acadia operates psychiatric hospitals, dozens of patients, employees and police officers have alerted the authorities that the company was detaining people in ways that violated the law, according to records reviewed by The Times. In some cases, judges have intervened to force Acadia to release patients." Following this news, Acadia Healthcare stock fell over 4% on September 3, 2024.
If you suffered a loss on your Acadia Healthcare Company, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into BrightSpring Health Services, Inc. (NASDAQ: BTSG) concerning potential violations of the federal securities laws.
BrightSpring conducted its initial public offering ("IPO") of 53,333,334 shares of common stock priced at $13.00 per share on or around January 25, 2024. Then, on August 2, 2024, BrightSpring issued a press release announcing its financial results for the second quarter of 2024. Among other items, BrightSpring reported non-GAAP earnings per share of $0.10, missing consensus estimates by $0.03 per share. Following this news, BrightSpring's stock price fell over 8% on August 2, 2024.
If you suffered a loss on your BrightSpring Health Services, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Dyne Therapeutics, Inc. (NASDAQ: DYN) concerning potential violations of the federal securities laws.
Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts." However, in a separate press release on that same day, Dyne announced that the Company's chief medical officer, chief operating officer, and chief business officer were "step[ping] down from their roles". Following this news, Dyne's stock price fell over 30% on September 3, 2024.
If you suffered a loss on your Dyne Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Bank of Montreal (NYSE: BMO) concerning potential violations of the federal securities laws.
On August 27, 2024, BoM reported its financial results for the third quarter of 2024, reporting adjusted earnings per share of C$2.64 (US$1.96), which missed consensus estimates for the third consecutive quarter. The Company also increased its provision for credit losses to C$906 million, compared to C$492 million for the same period in the prior year. In response, Jefferies downgraded BoM's stock to Hold from Buy. On this news, BoM's stock price fell over 6% to close at $83.30 per share on August 27, 2024.
If you suffered a loss on your BoM securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Deutsche Bank Aktiengesellschaft (NYSE: DB) concerning potential violations of the federal securities laws.
Deutsche Bank is the subject of a MarketWatch report published on July 24, 2024. According to the report, "Deutsche Bank said it lost €143 million ($155 million), or 28 eurocents a share in the second quarter, after a €1.3 billion provision for litigation on the takeover of Postbank, that it had flagged in April. That is its first loss since 2020, and Deutsche Bank executives said the size of the provision means the bank won't conduct any "top-up" stock buybacks the rest of the year." The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Deutsche Bank Aktiengesellschaft securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Icahn Enterprises L.P. (NASDAQ: IEP) concerning potential violations of the federal securities laws.
Icahn is the subject of a Barron's article published on August 19, 2024, that states, "The Securities and Exchange Commission on Monday announced charges against Carl Icahn and Icahn Enterprises ‘for failing to disclose information relating to Icahn's pledges of IEP securities as collateral to secure personal margin loans worth billions of dollars under agreements with various lenders.'" The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Icahn Enterprises L.P. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into WisdomTree, Inc. (NYSE: WT) concerning potential violations of the federal securities laws.
On August 6, 2024, WisdomTree disclosed that it had received a Wells Notice from the U.S. Securities and Exchange Commission (“SEC”) advising the Company that the SEC has made a “preliminary determination” to file an enforcement action “alleging violations of certain provisions of the U.S. federal securities laws.” Following this news, WisdomTree’s stock price fell over 2.5% the same day.
If you suffered a loss on your WisdomTree, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Temenos AG (OTC: TMSNY) concerning potential violations of the federal securities laws.
On February 15, 2024, securities analyst Hindenburg Research published a research report titled Temenos: Major Accounting Irregularities, Failed Products and An Illusive Turnaround. In the report, Hindenburg states it “uncovered hallmarks of manipulated earnings and major accounting irregularities [at Temenos]. This includes evidence of roundtripped revenue, sham partnerships, rampant pulling forward of contract renewals, backdated contracts, excessive capitalization of seemingly non-existent R&D investments and other classic accounting red flags.” For example, a former Temenos executive interviewed by Hindenburg stated that one major deal the Company promoted to investors was “a misrepresentation to the market of the reality of where the revenue was,” adding “I would question whether it really was a[n] above the board transaction or not.” The report is the product of Hindenburg’s four-month investigation in which it interviewed 25 former Temenos employees. Following this report, the price of Temenos’ American Depositary Receipts (“ADR”) fell over 28% on February 15, 2024.
If you suffered a loss on your Temenos AG securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Biomea Fusion, Inc. (NASDAQ: BMEA) concerning potential violations of the federal securities laws.
Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively." Following this news, shares of Biomea fell over 59% in after hours trading on the same day.
If you suffered a loss on your Biomea Fusion, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Liquidia Corporation (NASDAQ: LQDA) concerning potential violations of the federal securities laws.
On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases. The delay has been referred to as a "curveball scenario" by Needham, as the drug was expected to be approved for launch by 4Q24.
If you suffered a loss on your Liquidia Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Medifast, Inc. (NYSE: MED) concerning potential violations of the federal securities laws.
Medifast reported its quarterly earnings on April 29, 2024. The Company's adjusted earnings per share of $0.66 were considerably below Wall Street estimates of $0.80 per share and much lower than the same period in the previous year. Following this news, shares of Medifast fell over 22% in morning trading on April 30, 2024.
If you suffered a loss on your Medifast securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) concerning potential violations of the federal securities laws.
Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." The Company stated that its "decision is based on the results of a prespecified interim analysis of the trial," following which the Syros determined that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low[.]" Following this news, Syros's stock price fell over 61% on August 13, 2024.
If you suffered a loss on your Syros Pharmaceuticals securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Endeavour Silver Corp. (NYSE: EXK) concerning potential violations of the federal securities laws.
Endeavour issued a press release on August 12, 2024, disclosing that "the primary ball mill at the Guanacevi mill" in Mexico "has failed and could take up to 12 weeks to replace" and that "[a]s a result, processing of material at the Guanacevi mill has been suspended." The Company further stated that "this downtime will impact Q3 production and is expected to impact annual production and cost guidance." Following this news, Endeavour's stock price fell over 13% on August 12, 2024.
If you suffered a loss on your Endeavour Silver Corp. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





